{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:07:04Z","timestamp":1756462024372,"version":"3.37.3"},"reference-count":48,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"The Chinese PLA General Hospital","award":["YQPY-2020-001"],"award-info":[{"award-number":["YQPY-2020-001"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2020M682593"],"award-info":[{"award-number":["2020M682593"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Recent meta-analyses of randomized controlled trials have raised concerns that denosumab might increase the risk of infection. However, data of denosumab on the risk of community-acquired pneumonia are sparse.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This work aimed to examine the risk of community-acquired pneumonia in individuals receiving denosumab compared to those receiving alendronate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a propensity score-matched cohort study with a UK primary care database (IQVIA Medical Research Database). We examined the relation of denosumab to community-acquired pneumonia using a Cox proportional hazard model. The study participants were osteoporotic patients older than 45 years who were initiators of denosumab or alendronate from August 1, 2010, to September 17, 2020. The outcome measure was community-acquired pneumonia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Patients treated with denosumab (n\u2005=\u2005933) were compared with those treated with alendronate (n\u2005=\u20054652). In the matched population, the mean (SD) age was 77 (11) years, 89% were women, and about half of the study population had a history of major osteoporotic fracture. Over 5 years of follow-up, the incidence of community-acquired pneumonia per 1000 person-years was 72.0 (95% CI, 60.1-85.7) in the denosumab group and 75.1 (95% CI, 69.4-81.2) in the alendronate group. The hazard of community-acquired pneumonia was similar between denosumab and alendronate users (hazard ratio [HR] 0.96; 95% CI, 0.79-1.16). The results remained consistent in a series of sensitivity analyses, with HR ranging from 0.82 (95% CI, 0.65-1.04) to 0.99 (95% CI, 0.81-1.21).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Denosumab does not significantly increase the susceptibility of community-acquired pneumonia and could possibly be safely used for the management of osteoporosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgac262","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T16:54:51Z","timestamp":1651769691000},"page":"e3366-e3373","source":"Crossref","is-referenced-by-count":4,"title":["Denosumab and Risk of Community-acquired Pneumonia: A Population-based Cohort Study"],"prefix":"10.1210","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0128-0062","authenticated-orcid":false,"given":"Houchen","family":"Lyu","sequence":"first","affiliation":[{"name":"Department of Orthopaedic, Xiangya Hospital, Central South University , Changsha, 410008 , China"},{"name":"Department of Orthopedics, General Hospital of Chinese PLA , Beijing, 100853 , China"},{"name":"National Clinical Research Center for Orthopedics, Sports Medicine & Rehabilitation , Beijing, 100853 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sizheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre , Manchester, M139PL , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiatian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, Xiangya Hospital, Central South University , Changsha, 410008 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxiao","family":"Li","sequence":"additional","affiliation":[{"name":"Hunan Key Laboratory of Joint Degeneration and Injury , Changsha, 410008 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, Xiangya Hospital, Central South University , Changsha, 410008 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongxing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, Xiangya Hospital, Central South University , Changsha, 410008 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, Xiangya Hospital, Central South University , Changsha, 410008 , China"},{"name":"Hunan Key Laboratory of Joint Degeneration and Injury , Changsha, 410008 , China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University , Changsha, 410008 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2987-138X","authenticated-orcid":false,"given":"Guanghua","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, Xiangya Hospital, Central South University , Changsha, 410008 , China"},{"name":"Hunan Key Laboratory of Joint Degeneration and Injury , Changsha, 410008 , China"},{"name":"National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University , Changsha, 410008 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3510-8241","authenticated-orcid":false,"given":"Jie","family":"Wei","sequence":"additional","affiliation":[{"name":"Hunan Key Laboratory of Joint Degeneration and Injury , Changsha, 410008 , China"},{"name":"Health Management Center, Xiangya Hospital, Central South University , Changsha, 410008 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7184-592X","authenticated-orcid":false,"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic, Xiangya Hospital, Central South University , Changsha, 410008 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"issue":"5","key":"2022071417213826800_CIT0001","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov."},{"issue":"1","key":"2022071417213826800_CIT0002","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"2022071417213826800_CIT0003","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"2022071417213826800_CIT0004","article-title":"Secular trends in the pharmacologic treatment of osteoporosis and malignancy-related bone disease from 2009 to 2020","author":"Cromer","year":"2021","journal-title":"J Gen Intern Med."},{"issue":"9","key":"2022071417213826800_CIT0005","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00198-019-05064-w","article-title":"Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom","volume":"30","author":"Svedbom","year":"2019","journal-title":"Osteoporos Int."},{"issue":"8","key":"2022071417213826800_CIT0006","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"issue":"8","key":"2022071417213826800_CIT0007","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med."},{"issue":"5","key":"2022071417213826800_CIT0008","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.2249","article-title":"Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture","volume":"44","author":"Estrada","year":"2012","journal-title":"Nat Genet."},{"key":"2022071417213826800_CIT0009","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41232-019-0111-3","article-title":"RANKL biology: bone metabolism, the immune system, and beyond","volume":"40","author":"Ono","year":"2020","journal-title":"Inflamm Regen."},{"key":"2022071417213826800_CIT0010","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond","volume":"5","author":"Walsh","year":"2014","journal-title":"Front Immunol."},{"issue":"18","key":"2022071417213826800_CIT0011","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s00018-007-7104-0","article-title":"RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases","volume":"64","author":"Baud\u2019huin","year":"2007","journal-title":"Cell Mol Life Sci."},{"issue":"1","key":"2022071417213826800_CIT0012","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int."},{"issue":"5","key":"2022071417213826800_CIT0013","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1210\/clinem\/dgz322","article-title":"Risk for infections during treatment with denosumab for osteoporosis: a systematic review and meta-analysis","volume":"105","author":"Diker-Cohen","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"10303","key":"2022071417213826800_CIT0014","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(21)00630-9","article-title":"Community-acquired pneumonia","volume":"398","author":"Aliberti","year":"2021","journal-title":"Lancet."},{"issue":"6732","key":"2022071417213826800_CIT0015","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1136\/bmj.300.6732.1092","article-title":"The Read clinical classification","volume":"300","author":"Chisholm","year":"1990","journal-title":"BMJ."},{"author":"First Databank","key":"2022071417213826800_CIT0016"},{"issue":"4","key":"2022071417213826800_CIT0017","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pds.1335","article-title":"Validation studies of The Health Improvement Network (THIN) database for pharmacoepidemiology research","volume":"16","author":"Lewis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"2022071417213826800_CIT0018","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac262","article-title":"\u201cDenosumab and risk of community-acquired pneumonia: a population-based cohort study.\u201d","author":"Lyu","year":"2022"},{"issue":"12","key":"2022071417213826800_CIT0019","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1086\/426031","article-title":"Understanding the natural history of community-acquired pneumonia resolution: vital information for optimizing duration of therapy","volume":"39","author":"Niederman","year":"2004","journal-title":"Clin Infect Dis."},{"key":"2022071417213826800_CIT0020","doi-asserted-by":"crossref","first-page":"i5813","DOI":"10.1136\/bmj.i5813","article-title":"Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study","volume":"355","author":"Othman","year":"2016","journal-title":"BMJ."},{"issue":"7","key":"2022071417213826800_CIT0021","doi-asserted-by":"crossref","first-page":"516","DOI":"10.7326\/M20-0882","article-title":"Delayed denosumab injections and fracture risk among patients with osteoporosis: a population-based cohort study","volume":"173","author":"Lyu","year":"2020","journal-title":"Ann Intern Med."},{"issue":"6","key":"2022071417213826800_CIT0022","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med."},{"issue":"10","key":"2022071417213826800_CIT0023","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med."},{"key":"2022071417213826800_CIT0024","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac262","article-title":"\u201cDenosumab and risk of community-acquired pneumonia: a population-based cohort study.\u201d","author":"Lyu","year":"2022"},{"key":"2022071417213826800_CIT0025","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac262","article-title":"\u201cDenosumab and risk of community-acquired pneumonia: a population-based cohort study.\u201d","author":"Lyu","year":"2022"},{"key":"2022071417213826800_CIT0026","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgac262","article-title":"\u201cDenosumab and risk of community-acquired pneumonia: a population-based cohort study.\u201d","author":"Lyu","year":"2022"},{"issue":"9","key":"2022071417213826800_CIT0027","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/cid\/ciy723","article-title":"Prevalence and etiology of community-acquired pneumonia in immunocompromised patients","volume":"68","author":"Di Pasquale","year":"2019","journal-title":"Clin Infect Dis."},{"issue":"2","key":"2022071417213826800_CIT0028","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.cmi.2019.06.025","article-title":"Hospitalization due to community-acquired pneumonia in patients with chronic obstructive pulmonary disease: incidence, epidemiology and outcomes","volume":"26","author":"Bordon","year":"2020","journal-title":"Clin Microbiol Infect."},{"issue":"1","key":"2022071417213826800_CIT0029","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4049\/jimmunol.179.1.266","article-title":"Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection","volume":"179","author":"Miller","year":"2007","journal-title":"J Immunol."},{"issue":"11","key":"2022071417213826800_CIT0030","doi-asserted-by":"crossref","first-page":"7497","DOI":"10.4049\/jimmunol.179.11.7497","article-title":"Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses","volume":"179","author":"Stolina","year":"2007","journal-title":"J Immunol."},{"issue":"2","key":"2022071417213826800_CIT0031","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2011.04.001","article-title":"Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys","volume":"49","author":"Ominsky","year":"2011","journal-title":"Bone."},{"issue":"8","key":"2022071417213826800_CIT0032","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ng2076","article-title":"Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL","volume":"39","author":"Sobacchi","year":"2007","journal-title":"Nat Genet."},{"issue":"12","key":"2022071417213826800_CIT0033","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1359\/jbmr.2005.20.12.2274","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"20","author":"Bekker","year":"2005","journal-title":"J Bone Miner Res."},{"key":"2022071417213826800_CIT0034","first-page":"143","article-title":"RANKL inhibition: from mice to men (and women).","volume-title":"Osteoimmunology. Advances in Experimental Medicine and Biology","author":"Stolina","year":"2007"},{"issue":"10","key":"2022071417213826800_CIT0035","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1055\/s-0029-1224109","article-title":"Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis","volume":"41","author":"Anastasilakis","year":"2009","journal-title":"Horm Metab Res."},{"issue":"5","key":"2022071417213826800_CIT0036","first-page":"2113","article-title":"Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis","volume":"7","author":"Zhou","year":"2014","journal-title":"Int J Clin Exp Pathol."},{"issue":"2","key":"2022071417213826800_CIT0037","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12020-020-02500-4","article-title":"Are women with osteoporosis treated with denosumab at risk of severe COVID-19?","volume":"70","author":"Formenti","year":"2020","journal-title":"Endocrine."},{"issue":"5","key":"2022071417213826800_CIT0038","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1210\/clinem\/dgz321","article-title":"Delayed denosumab injections and bone mineral density response: an electronic health record-based study","volume":"105","author":"Lyu","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022071417213826800_CIT0039","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jcm10010152","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J Clin Med."},{"issue":"4","key":"2022071417213826800_CIT0040","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022071417213826800_CIT0041","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2022071417213826800_CIT0042","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial","volume":"28","author":"Brown","year":"2013","journal-title":"J Bone Miner Res."},{"key":"2022071417213826800_CIT0043","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone."},{"issue":"6","key":"2022071417213826800_CIT0044","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res."},{"issue":"6","key":"2022071417213826800_CIT0045","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/jbmr.4049","article-title":"Osteoporosis management in the era of COVID-19","volume":"35","author":"Yu","year":"2020","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2022071417213826800_CIT0046","first-page":"e4795","article-title":"Challenges and opportunities for osteoporosis care during the COVID-19 pandemic","volume":"106","author":"Cromer","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2022071417213826800_CIT0047","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol."},{"issue":"9","key":"2022071417213826800_CIT0048","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/jbmr.4030","article-title":"Nitrogen-containing bisphosphonates are associated with reduced risk of pneumonia in patients with hip fracture","volume":"35","author":"Sing","year":"2020","journal-title":"J Bone Miner Res."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac262\/43709251\/dgac262.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/8\/e3366\/44886226\/dgac262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/8\/e3366\/44886226\/dgac262.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T17:22:43Z","timestamp":1657819363000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/8\/e3366\/6577114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,3]]},"published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac262","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"type":"print","value":"0021-972X"},{"type":"electronic","value":"1945-7197"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,3]]}}}